Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Reinhard Dummer, Paolo Antonio Ascierto, Helen Gogas, Ana M. Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem de Groot, Naoya Yamazaki, Carmen Loquai, Laure A. De Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith Flaherty
Institutions: University of Zurich, University Hospital Zurich, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Hospital Clínic de Barcelona, Ospedale Papa Giovanni XXIII, National Institute of Oncology, University of Tübingen, University of Duisburg-Essen, Charles University, Medizinische Hochschule Hannover, Istituto Oncologico Veneto, Centre Hospitalier Universitaire de Bordeaux, Isala, National Cancer Center Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Novartis (Switzerland), Array BioPharma (United States), Institut Gustave Roussy, Massachusetts General Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2807744160